CG
Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
---|---|---|---|---|---|---|---|
Interleukin‐18 Binding Protein (IL‐18BP) Deficiency Affects Lymphocyte Activation and IL‐18 Expression in a Mouse Model of Liver Inflammation | European Journal of Immunology | 2025 | 65 | 33 | |||
Alerte au feu : des nanopompiers pour combattre les flammes de la polyarthrite rhumatoïde | Revue médicale suisse | 2024 | 146 | 11 | |||
Rhumatologie en crise : repenser la formation et les soins face à un défi croissant | Revue médicale suisse | 2024 | 5 | 0 | |||
Anti-apolipoprotein A-1 IgG, incident cardiovascular events, and lipid paradox in rheumatoid arthritis | Frontiers in cardiovascular medicine | 2024 | 91 | 100 | |||
Prospective registration of trials : where we are, why, and how we could get better | Journal of clinical epidemiology | 2024 | 24 | 30 | |||
Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studies | Joint bone spine | 2024 | 79 | 42 | |||
IL-18 Binding Protein–Producing Cells Attenuate Anemia in Murine Macrophage Activation Syndrome | The Journal of immunology | 2023 | 111 | 83 | |||
Impact of SARS-CoV2 infection on anti-apolipoprotein A-1 IgG response in inflammatory rheumatic diseases | Frontiers in immunology | 2023 | 107 | 54 | |||
Reporting and Representativeness of Race, Ethnicity, and Socioeconomic Status in Systemic Sclerosis Randomized Trials: An Observational Study | Arthritis care & research | 2023 | 53 | 41 | |||
Special Issue “IL-1 family cytokines in host defense, inflammation and cancer” | Cytokine | 2022 | 178 | 150 | |||
Long-term persistence of antibodies after diphtheria/tetanus vaccination in immunosuppressed patients with inflammatory rheumatic diseases and healthy controls | Vaccine | 2022 | 53 | 0 | |||
Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction Modeling | Arthritis & rheumatology | 2022 | 105 | 47 | |||
Systemic effects of IL-6 blockade in rheumatoid arthritis beyond the joints | Cytokine | 2022 | 173 | 169 | |||
Predictive value of anti-CarP and anti-PAD3 antibodies alone or in combination with RF and ACPA on the severity of rheumatoid arthritis | Rheumatology | 2021 | 356 | 361 | |||
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries | Rheumatology | 2021 | 221 | 0 | |||
Discrimination of COVID-19 from inflammation-induced cytokine storm syndromes using disease-related blood biomarkers | Arthritis and Rheumatology | 2021 | 170 | 231 | |||
Intracellular IL-1 receptor antagonist isoform 1 released from keratinocytes upon cell death acts as an inhibitor for the alarmin IL-1α | Journal of Immunology | 2020 | 344 | 2 | |||
Response to: 'When binary and continuous responses disagree' by Dr Ouyang | Annals of the Rheumatic Diseases | 2020 | 303 | 2 | |||
Evolving the comprehensive management of rheumatoid arthritis: identification of unmet needs and development of practical and educational tools | Clinical and Experimental Rheumatology | 2020 | 264 | 97 | |||
Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis | Arthritis Research and Therapy | 2020 | 387 | 138 | |||
IL-36 signaling in keratinocytes controls early IL-23 production in psoriasis-like dermatitis | Life Science Alliance | 2020 | 193 | 404 | |||
Individual therapeutic DAS28-d crit responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studies | Rheumatology International | 2020 | 217 | 69 | |||
Impact of acute inflammation on cytochromes P450 activity assessed by the Geneva Cocktail | Clinical Pharmacology and Therapeutics | 2020 | 300 | 405 | |||
Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities | RMD Open | 2020 | 115 | 49 | |||
IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome | Rheumatology | 2020 | 255 | 0 | |||
Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial | The Lancet | 2020 | 279 | 0 | |||
The role of the IL-1 system in pregnancy and the use of IL-1 system markers to identify women at risk for pregnancy complications† | Biology of Reproduction | 2020 | 138 | 0 | |||
IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome | Rheumatology | 2020 | 299 | 1 | |||
Production of IL-18 Binding Protein by Radiosensitive and Radioresistant Cells in CpG-Induced Macrophage Activation Syndrome | Journal of Immunology | 2020 | 264 | 1 | |||
Randomized clinical trials in ANCA-associated vasculitis: a systematic analysis of the WHO - International Clinical Trials Registry Platform | Orphanet Journal of Rare Diseases | 2020 | 139 | 109 | |||
Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes | Arthritis Research and Therapy | 2020 | 163 | 80 | |||
Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland | RMD Open | 2020 | 176 | 76 | |||
Detection of circulating highly expanded T-cell clones in at-risk individuals for rheumatoid arthritis before the clinical onset of the disease | Rheumatology | 2020 | 299 | 8 | |||
Travel patterns, risk behaviour and health problems of travellers with rheumatic diseases compared to controls: A multi-centre, observational study | Travel Medicine and Infectious Disease | 2020 | 149 | 0 | |||
Levels of CXCL13 and sICAM-1 correlate with disease activity score in patients with rheumatoid arthritis treated with tocilizumab | Advances in Rheumatology | 2019 | 267 | 111 | |||
Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution | Rheumatology | 2019 | 351 | 0 | |||
Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases-a prospective multi-centre cohort study | Rheumatology | 2019 | 289 | 0 | |||
The links of hepcidin and erythropoietin in the interplay of inflammation and iron deficiency in a large observational study of rheumatoid arthritis | British Journal of Haematology | 2019 | 240 | 0 | |||
Role of reproductive and menopausal factors in functional and structural progression of rheumatoid arthritis: results from the SCQM cohort | Rheumatology | 2019 | 255 | 0 | |||
Long-term therapy with anakinra in hidradenitis suppurativa in three patients | International Journal of Dermatology | 2019 | 300 | 1 | |||
Inadequate reporting of concomitant medications in rheumatology randomized controlled trials of pharmacologic interventions | Seminars in Arthritis and Rheumatism | 2019 | 262 | 0 | |||
Ultrasound is not associated with the presence of systemic autoimmunity or symptoms in individuals at risk for rheumatoid arthritis | RMD Open | 2019 | 314 | 79 | |||
Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis | Seminars in Arthritis and Rheumatism | 2019 | 294 | 161 | |||
Prevotella copri in individuals at risk for rheumatoid arthritis | Annals of the Rheumatic Diseases | 2019 | 422 | 0 | |||
Variable domain N-linked glycosylation and negative surface charge are key features of monoclonal ACPA: Implications for B-cell selection | European Journal of Immunology | 2018 | 380 | 0 | |||
Biological agents in the management of adult-onset Still's disease | Joint, Bone, Spine | 2018 | 396 | 282 | |||
Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration | Annals of the Rheumatic Diseases | 2018 | 441 | 1 | |||
Inflammasome Adaptor ASC Suppresses Apoptosis of Gastric Cancer Cells by an IL18-Mediated Inflammation-Independent Mechanism | Cancer Research | 2018 | 384 | 0 | |||
Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries | RMD Open | 2018 | 326 | 132 | |||
Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice | Blood | 2018 | 442 | 2 | |||
Regulation and function of interleukin-36 cytokines | Immunological Reviews | 2018 | 455 | 0 | |||
Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study | RMD Open | 2018 | 406 | 145 | |||
β Cell-Specific Deletion of the IL-1 Receptor Antagonist Impairs β Cell Proliferation and Insulin Secretion | Cell Reports | 2018 | 586 | 272 | |||
Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome | Blood | 2018 | 336 | 1 | |||
Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease | Annals of the Rheumatic Diseases | 2018 | 487 | 223 | |||
Comparison of Serological Biomarkers in Rheumatoid Arthritis and Their Combination to Improve Diagnostic Performance | Frontiers in Immunology | 2018 | 397 | 217 | |||
Incidence and prevalence of major adverse cardiovascular events in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis | Arthritis Care and Research | 2018 | 419 | 393 | |||
Nanocrystal-Polymer Particles: Extended Delivery Carriers for Osteoarthritis Treatment | Small | 2018 | 618 | 385 | |||
The perioperative use of synthetic and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis | Swiss Medical Weekly | 2017 | 564 | 281 | |||
Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis | Rheumatology | 2017 | 513 | 5 | |||
The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis | Clinical Rheumatology | 2017 | 594 | 3 | |||
Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition | Journal of Allergy and Clinical Immunology | 2017 | 420 | 2 | |||
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update | Annals of the Rheumatic Diseases | 2017 | 451 | 2 | |||
International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus | Autoimmunity Reviews | 2017 | 380 | 1 | |||
Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials | RMD Open | 2017 | 374 | 226 | |||
Cardiovascular risk in patients with rheumatoid arthritis | Seminars in Immunopathology | 2017 | 436 | 0 | |||
Rheumatoid arthritis: from basic findings and clinical manifestations to future therapies | Seminars in Immunopathology | 2017 | 334 | 0 | |||
Granzyme A Contributes to Inflammatory Arthritis in Mice Through Stimulation of Osteoclastogenesis | Arthritis and Rheumatology | 2017 | 524 | 0 | |||
Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration | Journal of Rheumatology | 2017 | 420 | 1 | |||
Salt-inducible kinases (SIK) inhibition reduces RANKL-induced osteoclastogenesis | PLOS ONE | 2017 | 511 | 149 | |||
Presence of IL-17 in synovial fluid identifies a potential inflammatory osteoarthritic phenotype | PloS one | 2017 | 541 | 223 | |||
IL-38 overexpression induces anti-inflammatory effects in mice arthritis models and in human macrophages in vitro | Annals of the Rheumatic Diseases | 2017 | 413 | 0 | |||
Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab | RMD Open | 2017 | 373 | 191 | |||
The role of female hormonal factors in the development of rheumatoid arthritis | Rheumatology | 2017 | 443 | 0 | |||
Deficiency in IL-1 Receptor Type 2 Aggravates K/BxN Serum Transfer-Induced Arthritis in Mice but Has No Impact on Systemic Inflammatory Responses | Journal of Immunology | 2017 | 740 | 2 | |||
The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis | Arthritis & rheumatology | 2016 | 498 | 0 | |||
A specific anti-citrullinated protein antibody profile identifies a group of rheumatoid arthritis patients with a toll-like receptor 4-mediated disease | Arthritis Research and Therapy | 2016 | 1,044 | 296 | |||
Distinct expression of interleukin (IL)-36α, β and γ, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease | Clinical and experimental immunology | 2016 | 527 | 2 | |||
Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis | Annals of the rheumatic diseases | 2016 | 521 | 221 | |||
Interleukin-36 potently stimulates human M2 macrophages, Langerhans cells and keratinocytes to produce pro-inflammatory cytokines | Cytokine | 2016 | 498 | 1 | |||
Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study | Annals of the rheumatic diseases | 2016 | 500 | 0 | |||
Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis | Rheumatology | 2016 | 509 | 0 | |||
IL-1R1-MyD88 axis elicits papain-induced lung inflammation | European Journal of Immunology | 2016 | 542 | 0 | |||
IL-36-Induced Toxicity in Neonatal Mice Involves TNF-α Production by Liver Myeloid Cells | Journal of Immunology | 2016 | 522 | 2 | |||
Elevated serum levels of free interleukin-18 in adult-onset Still's disease | Rheumatology | 2016 | 539 | 0 | |||
SIK inhibition in human myeloid cells modulates TLR and IL-1R signaling and induces an anti-inflammatory phenotype | Journal of leukocyte biology | 2016 | 495 | 1 | |||
Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration | Arthritis Research and Therapy | 2016 | 468 | 190 | |||
Effect of particle size on the biodistribution of nano- and microparticles following intra-articular injection in mice | International journal of pharmaceutics | 2016 | 859 | 4 | |||
The interleukin (IL)-1 cytokine family--Balance between agonists and antagonists in inflammatory diseases | Cytokine | 2015 | 271 | 0 | |||
Limited Contribution of IL-36 versus IL-1 and TNF Pathways in Host Response to Mycobacterial Infection | PloS one | 2015 | 545 | 208 | |||
Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry | Rheumatology | 2015 | 483 | 0 | |||
Atherosclerosis severity is not affected by a deficiency in IL-33/ST2 signaling | Immunity, inflammation and disease | 2015 | 1,160 | 178 | |||
The dermatologists' role in managing psoriatic arthritis: results of a Swiss Delphi exercise intended to improve collaboration with rheumatologists | Dermatology | 2015 | 439 | 0 | |||
Severe Neutrophil-Dominated Inflammation and Enhanced Myelopoiesis in IL-33-Overexpressing CMV/IL33 Mice | The Journal of immunology | 2015 | 662 | 2 | |||
Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases--a longitudinal study | Arthritis research & therapy | 2015 | 522 | 459 | |||
Inflammatory Articular Disease in Patients with Inflammatory Bowel Disease: Result of the Swiss IBD Cohort Study | Inflammatory bowel diseases | 2015 | 472 | 0 | |||
Intra-articular bioactivity of a p38 MAPK inhibitor and development of an extended-release system | European journal of pharmaceutics and biopharmaceutics | 2015 | 657 | 4 | |||
Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics | Arthritis research & therapy | 2014 | 550 | 334 | |||
Immune-mediated experimental arthritis in IL-33 deficient mice | Cytokine | 2014 | 652 | 0 | |||
Inflammation: IL-36 has proinflammatory effects in skin but not in joints | Nature reviews. Rheumatology | 2014 | 564 | 0 | |||
Adipokines correlate with pain in lower limb osteoarthritis: different associations in hip and knee | International orthopaedics | 2014 | 563 | 0 | |||
Joint damage progression in patients with rheumatoid arthritis in clinical remission. Do biologics perform better than synthetic antirheumatic drugs? | Journal of rheumatology | 2014 | 507 | 0 | |||
Traitement de fond de la polyarthrite rhumatoïde | Revue médicale suisse | 2014 | 275 | 2 | |||
Biological agents in monotherapy for the treatment of rheumatoid arthritis | Schweizerische medizinische Wochenschrift | 2014 | 569 | 2 | |||
In Black Africans with rheumatoid arthritis, ACPA recognize citrullinated fibrinogen and the derived peptides α36-50Cit38,42 and β60-74Cit60,72,74, like in Caucasians | Clinical immunology | 2014 | 600 | 1 | |||
Efficacy of intra-articular bevacizumab for relapsing diffuse-type giant cell tumour | Annals of the rheumatic diseases | 2014 | 639 | 2 | |||
Myeloid-related proteins 8 and 14 contribute to monosodium urate monohydrate crystal-induced inflammation in gout | Arthritis & rheumatology | 2014 | 689 | 0 | |||
The severity of experimental arthritis is independent of IL-36 receptor signaling | Arthritis research & therapy | 2013 | 613 | 233 | |||
Mouse neutrophils express the decoy type 2 interleukin-1 receptor (IL-1R2) constitutively and in acute inflammatory conditions | Journal of leukocyte biology | 2013 | 525 | 499 | |||
Reply to Xie et al. about the article "Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis" | Joint bone spine | 2013 | 552 | 0 | |||
Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement | Annals of the rheumatic diseases | 2013 | 674 | 463 | |||
Hand osteoarthritis: new insights | Joint bone spine | 2013 | 596 | 0 | |||
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions | Annals of the rheumatic diseases | 2013 | 599 | 361 | |||
Tocilizumab versus adalimumab for rheumatoid arthritis - Authors' reply | Lancet | 2013 | 513 | 0 | |||
Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL-33 deficiency | Arthritis research & therapy | 2013 | 624 | 257 | |||
Recommendations for the use of ultrasound in rheumatoid arthritis: literature review and SONAR score experience | Schweizerische medizinische Wochenschrift | 2013 | 813 | 403 | |||
Do synovial leptin levels correlate with pain in end stage arthritis? | International orthopaedics | 2013 | 653 | 168 | |||
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial | Lancet | 2013 | 622 | 0 | |||
The Activity of CCL18 is Principally Mediated through Interaction with Glycosaminoglycans | Frontiers in immunology | 2013 | 581 | 304 | |||
Endogenous IL-1α is a chromatin-associated protein in mouse macrophages | Cytokine | 2013 | 615 | 1 | |||
Coexistence of seropositive rheumatoid arthritis and SAPHO syndrome | Joint bone spine | 2013 | 615 | 0 | |||
Adalimumab in acute sciatica reduces the long-term need for surgery: a 3-year follow-up of a randomised double-blind placebo-controlled trial | Annals of the rheumatic diseases | 2012 | 653 | 0 | |||
Long-term amelioration of established collagen-induced arthritis achieved with short-term therapy combining anti-CD3 and anti-tumor necrosis factor treatments | Arthritis and rheumatism | 2012 | 563 | 1 | |||
Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists | Annals of the rheumatic diseases | 2012 | 544 | 395 | |||
Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis | Joint bone spine | 2012 | 723 | 696 | |||
Evaluation of cardiovascular risk in patients with rheumatoid arthritis: do cardiovascular biomarkers offer added predictive ability over established clinical risk scores? | Arthritis care & research | 2012 | 677 | 0 | |||
Mice deficient in hepatocyte-specific IL-1Ra show delayed resolution of concanavalin A-induced hepatitis | European Journal of Immunology | 2012 | 607 | 3 | |||
The mouse interleukin (Il)33 gene is expressed in a cell type- and stimulus-dependent manner from two alternative promoters | Journal of leukocyte biology | 2012 | 662 | 0 | |||
Investigation of Caucasian rheumatoid arthritis susceptibility loci in African patients with the same disease | Arthritis research & therapy | 2012 | 695 | 341 | |||
IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells | Blood | 2012 | 845 | 931 | |||
Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration | Annals of the rheumatic diseases | 2012 | 593 | 1 | |||
EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis | Annals of the rheumatic diseases | 2012 | 677 | 556 | |||
Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients | Annals of the rheumatic diseases | 2012 | 629 | 0 | |||
Articular inflammation is controlled by myeloid cell-derived interleukin 1 receptor antagonist during the acute phase of arthritis in mice | Annals of the rheumatic diseases | 2012 | 652 | 0 | |||
Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients | Haematologica | 2011 | 1,023 | 584 | |||
Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries | Annals of the rheumatic diseases | 2011 | 518 | 0 | |||
IL-36R ligands are potent regulators of dendritic and T cells | Blood | 2011 | 636 | 0 | |||
Spontaneous secretion of interleukin-17 and -22 by human cervical cells in Chlamydia trachomatis infection | Microbes and infection | 2011 | 600 | 0 | |||
Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial at a single center | Arthritis and rheumatism | 2011 | 624 | 0 | |||
Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study | Arthritis and rheumatism | 2011 | 853 | 8 | |||
IL-33 biology with potential insights into human diseases | Nature reviews. Rheumatology | 2011 | 592 | 0 | |||
Absence of up-regulation for a proliferation-inducing ligand in Sjögren's sialadenitis lesions | Rheumatology | 2011 | 655 | 1 | |||
The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study | Rheumatology | 2011 | 592 | 0 | |||
Autoimmunity and inflammation are independent of class II transactivator type PIV-dependent class II major histocompatibility complex expression in peripheral tissues during collagen-induced arthritis | Arthritis and rheumatism | 2011 | 634 | 0 | |||
Polyarthrite rhumatoïde,méthotrexate et fibrose pulmonaire : quelles évidences ? | Revue médicale suisse | 2010 | 783 | 1 | |||
Serum lipoproteins attenuate macrophage activation and Toll-Like Receptor stimulation by bacterial lipoproteins | BMC immunology | 2010 | 588 | 500 | |||
Distinct roles of hepatocyte- and myeloid cell-derived IL-1 receptor antagonist during endotoxemia and sterile inflammation in mice | The Journal of immunology | 2010 | 534 | 0 | |||
Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists | Joint bone spine | 2010 | 697 | 0 | |||
Enhanced Th1 and Th17 responses and arthritis severity in mice with a deficiency of myeloid cell-specific interleukin-1 receptor antagonist | Arthritis and rheumatism | 2010 | 597 | 0 | |||
Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients | Joint bone spine | 2010 | 595 | 0 | |||
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs | Annals of the rheumatic diseases | 2010 | 646 | 0 | |||
Diagnostic value of anti-cyclic citrullinated peptides and association with HLA-DRB1 shared epitope alleles in African rheumatoid arthritis patients | Arthritis research & therapy | 2010 | 721 | 521 | |||
Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis | Arthritis and rheumatism | 2010 | 869 | 3 | |||
IL-1 pathways in inflammation and human diseases | Nature reviews. Rheumatology | 2010 | 713 | 1 | |||
The effect of alcohol on radiographic progression in rheumatoid arthritis | Arthritis and rheumatism | 2010 | 579 | 0 | |||
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? | Annals of the rheumatic diseases | 2010 | 573 | 0 | |||
Adalimumab in severe and acute sciatica: a multicenter, randomized, double-blind, placebo-controlled trial | Arthritis and rheumatism | 2010 | 654 | 0 | |||
Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis | Arthritis and rheumatism | 2009 | 642 | 0 | |||
Clinical experience with mycophenolate mofetil in systemic autoimmune conditions refractory to common immunosuppressive therapies | Schweizerische medizinische Wochenschrift | 2009 | 611 | 282 | |||
Non-infectious lupus pericarditis: a retrospective hospital-based observation in Yaounde-Cameroon | Clinical rheumatology | 2009 | 573 | 0 | |||
Magnetically retainable microparticles for drug delivery to the joint: efficacy studies in an antigen-induced arthritis model in mice | Arthritis research & therapy | 2009 | 777 | 784 | |||
Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis | Arthritis and rheumatism | 2009 | 584 | 0 | |||
Mutations in the IL1RN locus lead to autoinflammation | Nature reviews. Rheumatology | 2009 | 568 | 0 | |||
Relationship between gamma-interferon and interleukin-17 in Chlamydia trachomatis reactive arthritis | Clinical and Experimental Rheumatology | 2009 | 544 | 0 | |||
Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure | Joint bone spine | 2009 | 546 | 0 | |||
The biological and clinical importance of the 'new generation' cytokines in rheumatic diseases | Arthritis research & therapy | 2009 | 585 | 166 | |||
Adaptive immune response in JAM-C-deficient mice: normal initiation but reduced IgG memory | The Journal of immunology | 2009 | 851 | 0 | |||
The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study | Annals of the rheumatic diseases | 2009 | 586 | 0 | |||
Interleukin-33 is biologically active independently of caspase-1 cleavage | The Journal of biological chemistry | 2009 | 644 | 479 | |||
Synovial tissues concentrate secreted APRIL | Arthritis research & therapy | 2009 | 627 | 354 | |||
The proinflammatory cytokine response to Chlamydia trachomatis elementary bodies in human macrophages is partly mediated by a lipoprotein, the macrophage infectivity potentiator, through TLR2/TLR1/TLR6 and CD14 | The Journal of immunology | 2008 | 600 | 0 | |||
Is tocilizumab a good therapeutic option for RA and systemic-onset juvenile idiopathic arthritis? | Nature reviews. Rheumatology | 2008 | 572 | 0 | |||
IL-1, IL-18, and IL-33 families of cytokines | Immunological reviews | 2008 | 876 | 3,542 | |||
Elevated levels of tumor necrosis factor-alpha in periradicular fat tissue in patients with radiculopathy from herniated disc | Spine | 2008 | 654 | 0 | |||
Impaired counter-regulation of interleukin-1 by the soluble IL-1 receptor type II in patients with chronic liver disease | Scandinavian journal of gastroenterology | 2008 | 613 | 0 | |||
The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33 | Cytokine | 2008 | 678 | 0 | |||
At the horizon of innovative therapy in rheumatology: new biologic agents | Current opinion in rheumatology | 2008 | 604 | 0 | |||
Molecular Characterization and Subcellular Localization of Macrophage Infectivity Potentiator, a Chlamydia trachomatis Lipoprotein | Journal of Bacteriology | 2007 | 729 | 693 | |||
Expression and function of junctional adhesion molecule-C in human and experimental arthritis | Arthritis research & therapy | 2007 | 632 | 333 | |||
Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells | Cytokine | 2007 | 504 | 0 | |||
B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents | Arthritis and rheumatism | 2007 | 157 | 1 | |||
Leukocyte migration to rheumatoid joints: Enzymes take over | Arthritis and rheumatism | 2006 | 571 | 1 | |||
Henoch Schönlein purpura following etanercept treatment of rheumatoid arthritis | Clinical and Experimental Rheumatology | 2006 | 525 | 0 | |||
The new IL-1 family member IL-1F8 stimulates production of inflammatory mediators by synovial fibroblasts and articular chondrocytes | Arthritis research & therapy | 2006 | 562 | 273 | |||
Intracellular interleukin-1 receptor antagonist type 1 antagonizes the stimulatory effect of interleukin-1 alpha precursor on cell motility | Cytokine | 2005 | 510 | 421 | |||
Delayed resolution of acute inflammation during zymosan-induced arthritis in leptin-deficient mice | Arthritis research & therapy | 2004 | 467 | 157 | |||
Total hip prosthetic joint infection due to Veillonella species | Joint bone spine | 2004 | 617 | 0 |